ImmuPharma plc (LON:IMM – Get Free Report) shares fell 15.3% on Wednesday . The company traded as low as GBX 4.60 ($0.06) and last traded at GBX 5 ($0.06). 57,070,488 shares changed hands during mid-day trading, an increase of 126% from the average session volume of 25,258,289 shares. The stock had previously closed at GBX 5.90 ($0.07).
ImmuPharma Stock Down 15.4 %
The company’s fifty day moving average price is GBX 1.92 and its two-hundred day moving average price is GBX 1.78. The company has a market cap of £20.78 million, a price-to-earnings ratio of -499.00 and a beta of 1.53.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
See Also
- Five stocks we like better than ImmuPharma
- Retail Stocks Investing, Explained
- Oklo’s Fuel Partnership Strengthens Bullish Case for Stock
- What is the Dow Jones Industrial Average (DJIA)?
- SLB: Pioneering the Shift from Oil Services to Tech Solutions
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Apple Swings to Outperformer: Is It a Buy Ahead of Earnings?
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
